Impact of Revisions to the Drug Pricing System on Sales of Medical Gases and Medical Services
First written in FY2018. 1 of 3 entries say "Worsened", first in FY2023. Latest entry: FY2026.
The whole theme swung hardest in 2018: 21 of 67 companies on the "Worse" side.
48 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Accordingly, if large-scale revisions are made in the future to medical service fees or drug prices in the medical products business, the Group's operating performance and financial position may be affected.」
The company continues to disclose the risk of future revisions to medical fees and drug prices against the backdrop of efforts to contain medical costs, as well as its response through product and service development. - FY2023WorsenedAnnual report
「Accordingly, if large-scale revisions are made in the future to medical service fees or drug prices in the medical products business, the Group's operating performance and financial position may be affected.」
Regarding the risk associated with the official drug price system, the scope of the risk has been expanded from conventional drug-price revisions to the possibility of large-scale future revisions to medical-service fees and drug prices against the backdrop of the declining birth rate, an aging population and efforts to contain medical costs. - FY2018First statedAnnual report
「The Group provides medical gases and medical services to medical institutions. Accordingly, changes to the official drug price system may affect sales of medical gases and medical services.」
The company disclosed, for the first time as an individual item, the impact of drug price revisions as an external institutional risk specific to the medical-related business.